Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial

被引:1
|
作者
Lafaurie, Matthieu [1 ,33 ]
Chevret, Sylvie [2 ,3 ]
Fontaine, Jean-Paul [4 ]
Mongiat-Artus, Pierre [5 ]
de Lastours, Victoire [6 ,7 ,8 ]
Escaut, Lelia [9 ]
Jaureguiberry, Stephane [9 ]
Bernard, Louis [10 ]
Bruyere, Franck [11 ]
Gatey, Caroline [12 ,15 ]
Abgrall, Sophie [13 ]
Ferreyra, Milagros [14 ]
Aumaitre, Hugues [14 ]
Aparicio, Caroline
Garrait, Valerie [16 ]
Meyssonnier, Vanina [17 ]
Bourgarit-Durand, Anne [18 ]
Chabrol, Amelie [19 ]
Piet, Emilie [20 ]
Talarmin, Jean-Philippe [21 ]
Morrier, Marine [22 ]
Canoui, Etienne [23 ]
Charlier, Caroline [23 ,24 ]
Etienne, Manuel [25 ]
Pacanowski, Jerome [26 ]
Grall, Nathalie [7 ,8 ,27 ]
Desseaux, Kristell [28 ]
Empana-Barat, Florence [29 ]
Madeleine, Isabelle [30 ]
Bercot, Beatrice [7 ,8 ,31 ]
Molina, Jean-Michel [32 ]
Lefort, Agnes [6 ,7 ,8 ]
机构
[1] Hop St Louis, Hop Lariboisiere, AP HP, Dept Infect Dis, Paris, France
[2] Hop St Louis, Dept Biostat, AP HP, Paris, France
[3] Univ Paris Diderot, Inserm S 717, Paris, France
[4] Hop St Louis, Emergency Dept, AP HP, Paris, France
[5] Hop St Louis, AP HP, Dept Urol, Paris, France
[6] Hop Beaujon, AP HP, Dept Internal Med, Clichy, France
[7] Univ Paris Cite, Infect Antimicrobials Modelling Evolut IAME Res Gr, UMR 1137, Paris, France
[8] Inserm, Paris, France
[9] Hop Bicetre, Dept Infect Dis, AP HP, Le Kremlin Bicetre, France
[10] CHRU Tours, Dept Infect Dis, Tours, France
[11] CHRU Tours, Dept Urol, Tours, France
[12] Hop Antoine Beclere, AP HP, Dept Internal Med, Clamart, France
[13] Univ Paris Saclay, Inserm, U1018, Le Kremlin Bictre, France
[14] Ctr Hosp Perpignan, Dept Infect Dis, Perpignan, France
[15] Hop Lariboisiere, AP HP, Dept Internal Med, Paris, France
[16] Ctr Hosp Intercommunal Creteil, Dept Internal Med, Creteil, France
[17] Grp Hosp Diaconesses Croix St Simon, Dept Internal Med & Infect Dis, Paris, France
[18] Hop Jean Verdier, AP HP, Dept Internal Med, Bondy, France
[19] Hop Sud Francilien, Dept Infect Dis, Corbeil Essonnes, France
[20] Ctr Hosp Annecy Genevois, Dept Infect Dis, Annecy, France
[21] Ctr Hosp Intercommunal Cornouaille, Dept Infect Dis, Quimper, France
[22] Ctr Hosp Dept La Roche Sur Yon, Dept Infect Dis, La Roche Sur Yon, France
[23] Hop Cochin, AP HP, Mobile Infect Dis Team, Paris, France
[24] Univ Paris Cite Hosp, AP HP, French Natl Reference Ctr Listeria, Inst Pasteur,Biol Infect Unit,Inserm,U1117, Paris, France
[25] Hop Charles Nicolle, Dept Infect Dis, Rouen, France
[26] Hop St Antoine, Dept Infect Dis, AP HP, Paris, France
[27] Hop Bichat Claude Bernard, Dept Bacteriol, AP HP, Paris, France
[28] Hop St Louis, Dept Biostat, AP HP, Paris, France
[29] Agence Gen Equipements & Prod St, Clin Trial Dept, AP, Paris, France
[30] Hop St Louis, Pharm, AP HP, Paris, France
[31] Hop St Louis, Hop Lariboisiere, Dept Microbiol, AP HP, Paris, France
[32] Univ Paris Cite, Inserm, UMR 941, Paris, France
[33] Hop St Louis, Infect Dis Dept, 1 Ave Claude Vellefaux, F-75010 Paris, France
关键词
urinary tract infection; men; antibiotic duration; ofloxacin; ANTIBIOTIC-TREATMENT; DURATION;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this multicenter randomized, double-blind placebo-controlled noninferiority trial, 240 men were assigned to receive antibiotic therapy for 7 (115 participants) or 14 days (125 participants) for febrile urinary tract infection. A treatment for 7 days was inferior to 14 days. Background The optimal duration of antimicrobial therapy for urinary tract infections (UTIs) in men remains controversial. Methods To compare 7 days to 14 days of total antibiotic treatment for febrile UTIs in men, this multicenter randomized, double-blind. placebo-controlled noninferiority trial enrolled 282 men from 27 centers in France. Men were eligible if they had a febrile UTI and urine culture showing a single uropathogen. Participants were treated with ofloxacin or a third-generation cephalosporin at day 1, then randomized at day 3-4 to either continue ofloxacin for 14 days total treatment, or for 7 days followed by placebo until day 14. The primary endpoint was treatment success, defined as a negative urine culture and the absence of fever and of subsequent antibiotic treatment between the end of treatment and 6 weeks after day 1. Secondary endpoints included recurrent UTI within weeks 6 and 12 after day 1, rectal carriage of antimicrobial-resistant Enterobacterales, and drug-related events. Results Two hundred forty participants were randomly assigned to receive antibiotic therapy for 7 days (115 participants) or 14 days (125 participants). In the intention-to-treat analysis, treatment success occurred in 64 participants (55.7%) in the 7-day group and in 97 participants (77.6%) in the 14-day group (risk difference, -21.9 [95% confidence interval, -33.3 to -10.1]), demonstrating inferiority. Adverse events during antibiotic therapy were reported in 4 participants in the 7-day arm and 7 in the 14-day arm. Rectal carriage of resistant Enterobacterales did not differ between both groups. Conclusions A treatment with ofloxacin for 7 days was inferior to 14 days for febrile UTI in men and should therefore not be recommended.
引用
收藏
页码:2154 / 2162
页数:9
相关论文
共 50 条
  • [1] Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double Blind Placebo-controlled, Randomized Clinical Trial
    Clemens, J. Quentin
    JOURNAL OF UROLOGY, 2023, 210 (02): : 365 - 366
  • [2] POSTCOITAL ANTIMICROBIAL PROPHYLAXIS FOR RECURRENT URINARY-TRACT INFECTION - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    STAPLETON, A
    LATHAM, RH
    JOHNSON, C
    STAMM, WE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (06): : 703 - 706
  • [3] Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women
    van Nieuwkoop, Cees
    van der Starre, Willize E.
    Stalenhoef, Janneke E.
    van Aartrijk, Anna M.
    van der Reijden, Tanny J. K.
    Vollaard, Albert M.
    Delfos, Nathalie M.
    van 't Wout, Jan W.
    Blom, Jeanet W.
    Spelt, Ida C.
    Leyten, Eliane M. S.
    Koster, Ted
    Ablij, Hans C.
    van der Beek, Martha T.
    Knol, Mirjam J.
    van Dissel, Jaap T.
    BMC MEDICINE, 2017, 15
  • [4] Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women
    Cees van Nieuwkoop
    Willize E. van der Starre
    Janneke E. Stalenhoef
    Anna M. van Aartrijk
    Tanny J. K. van der Reijden
    Albert M. Vollaard
    Nathalie M. Delfos
    Jan W. van ’t Wout
    Jeanet W. Blom
    Ida C. Spelt
    Eliane M. S. Leyten
    Ted Koster
    Hans C. Ablij
    Martha T. van der Beek
    Mirjam J. Knol
    Jaap T. van Dissel
    BMC Medicine, 15
  • [5] Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)
    Cees van Nieuwkoop
    Jan W van't Wout
    Willem JJ Assendelft
    Henk W Elzevier
    Eliane MS Leyten
    Ted Koster
    G Hanke Wattel-Louis
    Nathalie M Delfos
    Hans C Ablij
    Ed J Kuijper
    Jan Pander
    Jeanet W Blom
    Ida C Spelt
    Jaap T van Dissel
    BMC Infectious Diseases, 9
  • [6] Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)
    van Nieuwkoop, Cees
    van't Wout, Jan W.
    Assendelft, Willem J. J.
    Elzevier, Henk W.
    Leyten, Eliane M. S.
    Koster, Ted
    Wattel-Louis, G. Hanke
    Delfos, Nathalie M.
    Ablij, Hans C.
    Kuijper, Ed J.
    Pander, Jan
    Blom, Jeanet W.
    Spelt, Ida C.
    van Dissel, Jaap T.
    BMC INFECTIOUS DISEASES, 2009, 9
  • [7] Re: Treatment Duration of Febrile Urinary Tract Infection: A Pragmatic Randomized, Double-blind, Placebo-controlled Non-inferiority Trial in Men and Women
    Grabe, Magnus J.
    EUROPEAN UROLOGY, 2017, 72 (04) : 652 - 652
  • [8] Salvia miltiorrhiza Root Extract for Men with Lower Urinary Tract Symptoms: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Shin, Dongho
    Moon, Hyong Woo
    Bae, Woong Jin
    Ha, U-Syn
    Park, Young Ho
    Lee, Eun Joo
    Moon, Du Geon
    Kim, Sae Woong
    NUTRIENTS, 2025, 17 (01)
  • [9] Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms
    Gerber, GS
    Kuznetsov, D
    Johnson, BC
    Burstein, JD
    UROLOGY, 2001, 58 (06) : 960 - 963
  • [10] Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms - Comment
    Wilt, TJ
    UROLOGY, 2001, 58 (06) : 964 - 965